About this episode

Brett Monia, Ph.D., discusses the evolution of antisense oligonucleotides and Ionis Pharmaceuticals' strategic shift to a wholly-owned pipeline.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brett Monia, Ph.D., CEO at Ionis Pharmaceuticals, talks about how antisense oligonucleotides (ASO) graduated from a late-1980s lab concept to real RNA-targeting medicines, and why Ionis stuck with a difficult modality despite multiple setbacks. Brett describes the company's shift from a partner-first model to building a wholly-owned pipeline, commercial function, and an expanded manufact...

People in this episode

Host: Ben Comer

Guest: Brett Monia, Ph.D.

Topics covered

• antisense oligonucleotides
• RNA-targeting medicines
• wholly-owned pipeline
• biotech management
• pharmaceutical development

Keywords

• ASO therapies
• Ionis Pharmaceuticals
• RNA-targeting
• biotech
• pharmaceuticals
• CEO
• pipeline development

Mentioned in this episode

Organizations: Ionis Pharmaceuticals

Explore listener stats, chart rankings, contacts and more on the Business Of Biotech podcast page.